Equities analysts expect Sarepta Therapeutics (NASDAQ:SRPT) to post $70.92 million in sales for the current quarter, Zacks reports. Nine analysts have issued estimates for Sarepta Therapeutics’ earnings, with the lowest sales estimate coming in at $69.00 million and the highest estimate coming in at $73.22 million. Sarepta Therapeutics posted sales of $35.01 million during the same quarter last year, which would indicate a positive year over year growth rate of 102.6%. The company is expected to announce its next quarterly earnings results on Wednesday, July 18th.
According to Zacks, analysts expect that Sarepta Therapeutics will report full-year sales of $298.22 million for the current year, with estimates ranging from $285.40 million to $308.66 million. For the next fiscal year, analysts anticipate that the firm will post sales of $438.89 million per share, with estimates ranging from $362.54 million to $519.50 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Sarepta Therapeutics.
Get Sarepta Therapeutics alerts:
Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Thursday, May 3rd. The biotechnology company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.23). Sarepta Therapeutics had a negative net margin of 83.88% and a negative return on equity of 24.68%. The company had revenue of $64.60 million during the quarter, compared to the consensus estimate of $65.31 million. During the same period last year, the firm posted ($0.57) EPS. The company’s revenue was up 295.3% on a year-over-year basis.
A number of equities research analysts have recently weighed in on the company. Credit Suisse Group reissued a “hold” rating and issued a $81.00 target price on shares of Sarepta Therapeutics in a research note on Monday, March 12th. Leerink Swann boosted their price target on Sarepta Therapeutics from $88.00 to $121.00 and gave the company an “outperform” rating in a report on Tuesday, May 15th. BidaskClub downgraded Sarepta Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, March 29th. HC Wainwright set a $75.00 price target on Sarepta Therapeutics and gave the company a “buy” rating in a report on Monday, February 12th. Finally, Goldman Sachs boosted their price target on Sarepta Therapeutics from $84.00 to $127.00 and gave the company a “buy” rating in a report on Friday. One investment analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $89.55.
Hedge funds have recently bought and sold shares of the business. LPL Financial LLC purchased a new position in shares of Sarepta Therapeutics during the 4th quarter worth approximately $643,000. Jennison Associates LLC grew its holdings in shares of Sarepta Therapeutics by 0.6% during the 4th quarter. Jennison Associates LLC now owns 1,150,210 shares of the biotechnology company’s stock worth $63,998,000 after acquiring an additional 6,357 shares during the period. BlackRock Inc. grew its holdings in shares of Sarepta Therapeutics by 0.9% during the 4th quarter. BlackRock Inc. now owns 6,286,343 shares of the biotechnology company’s stock worth $349,773,000 after acquiring an additional 58,433 shares during the period. TimesSquare Capital Management LLC grew its holdings in shares of Sarepta Therapeutics by 3.5% during the 4th quarter. TimesSquare Capital Management LLC now owns 491,250 shares of the biotechnology company’s stock worth $27,333,000 after acquiring an additional 16,800 shares during the period. Finally, Hall Laurie J Trustee grew its holdings in shares of Sarepta Therapeutics by 2,430.8% during the 4th quarter. Hall Laurie J Trustee now owns 3,290 shares of the biotechnology company’s stock worth $224,000 after acquiring an additional 3,160 shares during the period. Hedge funds and other institutional investors own 86.32% of the company’s stock.
Shares of Sarepta Therapeutics traded down $1.61, reaching $89.22, during midday trading on Thursday, according to Marketbeat Ratings. The company had a trading volume of 901,062 shares, compared to its average volume of 1,495,963. Sarepta Therapeutics has a one year low of $28.82 and a one year high of $95.67. The company has a current ratio of 13.37, a quick ratio of 12.28 and a debt-to-equity ratio of 0.55. The firm has a market cap of $6.13 billion, a PE ratio of -54.40 and a beta of 1.34.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Get a free copy of the Zacks research report on Sarepta Therapeutics (SRPT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
